Skip to content
OpenCapital
Get started

Organon OGN Other Cardiovascular — Revenue

Other product segments

Nexplanon/Implanon NXT
$201M-19.0%
Other
$87M+11.5%
Zetia
$87M+2.4%
Atozet
$85M+10.4%
Other Non-Opiod Pain, Bone and Dermatology
$68M0.0%
Hadlima
$67M+42.6%
Nasonex
$65M-9.7%
Follistim AQ
$61M-11.6%
Arcoxia
$59M-4.8%
Cozaar/Hyzaar
$57M+3.6%
Renflexis
$57M0.0%
Emgality
$54M+68.8%
Other Women's Health
$46M+7.0%
Singulair
$40M-45.9%
Diprospan
$35M+16.7%
Dulera
$35M-18.6%
Clarinex
$31M-8.8%
Propecia
$30M+15.4%
Fosamax
$29M-12.1%
Ganirelix Acetate Injection
$26M-3.7%
Marvelon/Mercilon
$26M-33.3%
Proscar
$26M+8.3%
Vtama
$25M+4.2%
NuvaRing
$24M+9.1%
Other Biosimilars
$24M—
Vytorin
$21M-8.7%
Brenzys
$20M+42.9%
Other Respiratory
$12M-7.7%
Rosuzet
$6M+50.0%
Jada
$5M-66.7%
Ontruzant
$5M-72.2%

Similar metrics at other companies

Johnson & Johnson logo
JNJother cardiovascular — Sales to Customers
$99.25M+4.5%
Eli Lilly logo
LLYOther cardiometabolic health — Revenue
$905M-4.2%
Johnson & Johnson logo
JNJother cardiovascular — % Change
1.1%-0.7pp
Medtronic logo
MDTCardiovascular — Net Sales
$3.8B+13.8%
Boston Scientific logo
BSXCardiovascular — Net Sales
$3.5B+13.5%
Lantheus Holdings logo
LNTHCardiology — Revenue
$84.63M+6.8%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%
Enterprise value$10.98B-26.4%
P/E6.6×+2.1×
P/S0.6×-0.8×

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's other cardiovascular — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's other cardiovascular — revenue?
Organon (OGN) reported other cardiovascular — revenue of $28M in Q1 2026.
How has Organon's other cardiovascular — revenue changed year-over-year?
Organon's other cardiovascular — revenue decreased by 6.7% year-over-year, from $30M to $28M.
What is the long-term trend for Organon's other cardiovascular — revenue?
Over 4 years (2021 to 2025), Organon's other cardiovascular — revenue has grown at a -10.2% compound annual growth rate (CAGR), from $192M to $125M.
What does other cardiovascular — revenue mean?
This metric represents the total net sales generated from the company's portfolio of cardiovascular pharmaceutical products that fall outside of its primary or lead therapeutic franchises. It reflects the market demand and commercial performance of these established or secondary cardiovascular therapies within the broader product mix. Monitoring this revenue stream helps investors assess the contribution and lifecycle maturity of the company's secondary cardiovascular assets.